TD Cowen Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $371
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Ritu Baral maintains a Buy rating on Alnylam Pharmaceuticals and raises the price target from $282 to $371.
October 21, 2024 | 12:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TD Cowen has reiterated its Buy rating for Alnylam Pharmaceuticals and increased the price target from $282 to $371, indicating a positive outlook on the company's stock.
The increase in price target from $282 to $371 by TD Cowen suggests a strong positive sentiment towards Alnylam Pharmaceuticals' future performance. This is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100